stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Gross margin
Novo Nordisk A/S's gross margin over the twelve months to 30 June 2026 was 80.7%, down 0.2 percentage points from fiscal 2025 (81.0%). Over the past ten years it has ranged from 81.0% (fiscal 2025) to 85.0% (fiscal 2015) — the current reading is the lowest in ten years. That is above the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 81.0% | (3.69) |
| FY2024 | 84.7% | 0.07 |
| FY2023 | 84.6% | 0.68 |
| FY2022 | 83.9% | 0.72 |
| FY2021 | 83.2% | (0.31) |
| FY2020 | 83.5% | (0.03) |
| FY2019 | 83.5% | (0.71) |
| FY2018 | 84.3% | 0.04 |
| FY2017 | 84.2% | (0.42) |
| FY2016 | 84.6% | (0.37) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 78.2% | (7.75) |
| Mar 2026 | 86.0% | 4.79 |
| Dec 2025 | 81.2% | 5.05 |
| Sep 2025 | 76.1% | (7.17) |
| 42 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| SNY Sanofi compare | 73.4% |
| PFE Pfizer Inc. compare | 73.4% |
| GSK GSK PLC Sponsored ADR compare | 72.6% |
| AMGN Amgen Inc. compare | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on NVO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement